Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of HR19042 in Healthy Chinese Subjects
NCT04887532Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jul 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HR19042 in IgA nephropathy (IgAN) (3 arms), sponsored by Hengrui. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration and 1 more. Started Jul 2021; status: completed.
02
Drugs
HR19042
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT04887532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04887532.